General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises CytomX Therapeutics in its US$100 Million Public Offering

January 22, 2021
A corporate team represents the biopharmaceutical company in the transaction.

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, has announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock at a price to the public of US$7.00 per share, for gross proceeds of US$100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by CytomX. All shares are being offered by CytomX. In addition, CytomX has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of its common stock at the public offering price, on the same terms and conditions. 

Latham & Watkins LLP represents CytomX Therapeutics, Inc. in the transaction with a corporate deal team led by Bay Area partners Mark Roeder and Miles Jennings, with associates Tess Bloom and Madelyn Tarr. Advice is also provided on tax matters by Bay Area partner Katharine Moir; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Barrett Tenbarge; and on intellectual property matters by Bay Area partner Judith Hasko, with associate Peggy Ni.